Committee advances CAR‑T advisory council bill amid concerns about duplication and conflicts
Loading...
Summary
Senate Bill 451 to create an advisory council advising the Department of Public Health on CAR‑T and gene‑therapy delivery, training, and referrals was moved JFS after debate; opponents said it duplicates federal oversight and accreditation while supporters said a state council can improve access and coordinate grants for rare diseases such as sickle cell.
A public‑health committee voted to advance Senate Bill 451 to the floor after extended discussion about the proposed advisory council on CAR‑T and other gene therapies.
The measure would create a council within the Department of Public Health to make recommendations on safely and equitably delivering these therapies, develop referral and management protocols, advise on advanced training for clinicians, and prepare an annual report for this committee and the insurance committee. The bill would also authorize the council to apply for and accept grants and enter contracts or agreements to distribute funds.
Senator Gordon (speaker 16), a practicing hematologist/oncologist who said he refers patients for CAR‑T, argued the council would be duplicative of existing federal oversight, national accreditation and hospital protocols. "I don't see that what this bill actually serves in the real world," he told colleagues, saying hospitals and accredited cancer centers already have extensive safety and training measures in place. He also raised a question about conflicts of interest if the council is allowed to accept grants and gifts.
Senator Ammar (speaker 4) and other supporters said a state advisory council would help coordinate access and funding, especially for non‑oncologic uses of gene therapy and for rarer conditions such as sickle cell, where federal grants and coordinated state efforts can improve patient access. Ammar said coordination could help secure federal grants and ensure patients statewide can receive treatments when appropriate.
The committee recorded differing views but moved the bill by motion to JFS. Senator Gordon said he would vote no; other members who spoke said they would support the measure with the expectation that language on conflicts of interest, scope, and potential duplication would be addressed in subsequent drafting.
The committee's action advances the proposal to the floor for further consideration, with the expectation of more detailed statutory language to address oversight and funding safeguards.
